Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 54Leukemia 30Lymphoma, Extranodal NK-T-Cell 21Lymphoma 9Recurrence 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Lymphohistiocytosis, Hemophagocytic 5Burkitt Lymphoma 4Leukemia, T-Cell 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm, Residual 2Lymphoma, Non-Hodgkin 2Leukemia, Biphenotypic, Acute 2Epstein-Barr Virus Infections 2Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Mucositis 1Lymphoma, T-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Blast Crisis 1

Interventions

Rituximab 7Valganciclovir 5Valacyclovir 3Gemcitabine 3Dexamethasone 3Cisplatin 3spartalizumab 2pegaspargase 2Radiotherapy, Intensity-Modulated 2Methylprednisolone 2Lenalidomide 2Etoposide 2Doxorubicin 2Cell Count 2Blood Specimen Collection 2valomaciclovir 1toripalimab 1ruxolitinib 1pembrolizumab 1merphos 1fludarabine 1dehydroftorafur 1avelumab 1apatinib 1Zidovudine 1Watchful Waiting 1Valproic Acid 1Vaccines 1Tenofovir 1Tegafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Epstein-Barr Virus Infections × pegaspargase × Clear all
NCT02912702 2016-09-23

L-DEP as an Initial Treatment for EBV-HLH

Beijing Friendship Hospital

Phase 3 Unknown
120 enrolled
Myeloid

Epstein-Barr Virus Infections, Lymphohistiocytosis, Hemophagocytic

NCT02631109 2016-08-04

L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis

Beijing Friendship Hospital

Phase 3 Unknown
120 enrolled
Myeloid

Epstein-Barr Virus Infections, Lymphohistiocytosis, Hemophagocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡